Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Guidelines for the safe administration of high-dose interleukin-2
Autore:
Schwartzentruber, DJ;
Indirizzi:
NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 4, volume: 24, anno: 2001,
pagine: 287 - 293
SICI:
1524-9557(200107/08)24:4<287:GFTSAO>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
199 CONSECUTIVE PATIENTS; RENAL-CELL CARCINOMA; METASTATIC MELANOMA; CANCER; TOXICITY;
Keywords:
high-dose IL-2; toxicity; melanoma; renal cell carcinoma;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Schwartzentruber, DJ NCI, Surg Branch, NIH, Bldg 10,Room 2B0b, Bethesda, MD 20892 USA NCI Bldg 10,Room 2B0b Bethesda MD USA 20892 20892 USA
Citazione:
D.J. Schwartzentruber, "Guidelines for the safe administration of high-dose interleukin-2", J IMMUNOTH, 24(4), 2001, pp. 287-293

Abstract

High-dose interleukin-2 (IL-2) results in objective clinical regression ofmetastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8%of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients withmetastatic melanoma and renal cell carcinoma. Interleukin-2 administrationis associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-doseIL-2.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 14:48:21